CD47 as a promising therapeutic target in oncology

CD47 is ubiquitously expressed on the surface of cells and plays a critical role in self-recognition. By interacting with SIRPα, TSP-1 and integrins, CD47 modulates cellular phagocytosis by macrophages, determines life span of individual erythrocytes, regulates activation of immune cells, and manipu...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology Vol. 13; p. 757480
Main Authors: Zhao, Hai, Song, Shuangshuang, Ma, Junwei, Yan, Zhiyong, Xie, Hongwei, Feng, Ying, Che, Shusheng
Format: Journal Article
Language:English
Published: Frontiers Media S.A 22.08.2022
Subjects:
atherosclerosis
cancer immunotherapy
CD47
immune modulation
Immunology
immunotherapies
SIRPα
ISSN:1664-3224, 1664-3224
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract CD47 is ubiquitously expressed on the surface of cells and plays a critical role in self-recognition. By interacting with SIRPα, TSP-1 and integrins, CD47 modulates cellular phagocytosis by macrophages, determines life span of individual erythrocytes, regulates activation of immune cells, and manipulates synaptic pruning during neuronal development. As such, CD47 has recently be regarded as one of novel innate checkpoint receptor targets for cancer immunotherapy. In this review, we will discuss increasing awareness about the diverse functions of CD47 and its role in immune system homeostasis. Then, we will discuss its potential therapeutic roles against cancer and outlines, the possible future research directions of CD47- based therapeutics against cancer.
AbstractList CD47 is ubiquitously expressed on the surface of cells and plays a critical role in self-recognition. By interacting with SIRPα, TSP-1 and integrins, CD47 modulates cellular phagocytosis by macrophages, determines life span of individual erythrocytes, regulates activation of immune cells, and manipulates synaptic pruning during neuronal development. As such, CD47 has recently be regarded as one of novel innate checkpoint receptor targets for cancer immunotherapy. In this review, we will discuss increasing awareness about the diverse functions of CD47 and its role in immune system homeostasis. Then, we will discuss its potential therapeutic roles against cancer and outlines, the possible future research directions of CD47- based therapeutics against cancer.CD47 is ubiquitously expressed on the surface of cells and plays a critical role in self-recognition. By interacting with SIRPα, TSP-1 and integrins, CD47 modulates cellular phagocytosis by macrophages, determines life span of individual erythrocytes, regulates activation of immune cells, and manipulates synaptic pruning during neuronal development. As such, CD47 has recently be regarded as one of novel innate checkpoint receptor targets for cancer immunotherapy. In this review, we will discuss increasing awareness about the diverse functions of CD47 and its role in immune system homeostasis. Then, we will discuss its potential therapeutic roles against cancer and outlines, the possible future research directions of CD47- based therapeutics against cancer.
CD47 is ubiquitously expressed on the surface of cells and plays a critical role in self-recognition. By interacting with SIRPα, TSP-1 and integrins, CD47 modulates cellular phagocytosis by macrophages, determines life span of individual erythrocytes, regulates activation of immune cells, and manipulates synaptic pruning during neuronal development. As such, CD47 has recently be regarded as one of novel innate checkpoint receptor targets for cancer immunotherapy. In this review, we will discuss increasing awareness about the diverse functions of CD47 and its role in immune system homeostasis. Then, we will discuss its potential therapeutic roles against cancer and outlines, the possible future research directions of CD47- based therapeutics against cancer.
Author Song, Shuangshuang
Yan, Zhiyong
Xie, Hongwei
Zhao, Hai
Ma, Junwei
Che, Shusheng
Feng, Ying
AuthorAffiliation 1 Department of Neurosurgery, the Affiliated Hospital of Qingdao University , Qingdao , China
2 Department of Nuclear Medicine, the Affiliated Hospital of Qingdao University , Qingdao , China
3 Department of Emergency, the Affiliated Hospital of Qingdao University , Qingdao , China
AuthorAffiliation_xml – name: 1 Department of Neurosurgery, the Affiliated Hospital of Qingdao University , Qingdao , China
– name: 2 Department of Nuclear Medicine, the Affiliated Hospital of Qingdao University , Qingdao , China
– name: 3 Department of Emergency, the Affiliated Hospital of Qingdao University , Qingdao , China
Author_xml – sequence: 1
  givenname: Hai
  surname: Zhao
  fullname: Zhao, Hai
– sequence: 2
  givenname: Shuangshuang
  surname: Song
  fullname: Song, Shuangshuang
– sequence: 3
  givenname: Junwei
  surname: Ma
  fullname: Ma, Junwei
– sequence: 4
  givenname: Zhiyong
  surname: Yan
  fullname: Yan, Zhiyong
– sequence: 5
  givenname: Hongwei
  surname: Xie
  fullname: Xie, Hongwei
– sequence: 6
  givenname: Ying
  surname: Feng
  fullname: Feng, Ying
– sequence: 7
  givenname: Shusheng
  surname: Che
  fullname: Che, Shusheng
BookMark eNp1kUtrHDEMx01JaR7NB-htjr3sxg_5dSmU7SsQ6KU9G9njmTjMjLceTyHfPrO7KTSF6iIh6f9D6H9JzqY8RULeMboVwtibLo3jsuWU862WGgx9RS6YUrARnMPZX_U5uZ7nB7oGWCGEfEPOhaKGgTUXhO8-gW5wbrDZlzymOU19U-9jwX1cagpNxdLH2qSpyVPIQ-4f35LXHQ5zvH7OV-Tnl88_dt82d9-_3u4-3m0CAK-bTgTBtWBd8FZ3SgtqYpQyKKahNQYBvRS0MyFYFQzazgtDZeSSmhakR3FFbk_cNuOD25c0Ynl0GZM7NnLpHZb1xCE6oanmXiDzXoK16GnLpYEoFcggWr-yPpxY-8WPsQ1xqgWHF9CXkynduz7_dhZAaQkr4P0zoORfS5yrW38V4jDgFPMyO64ZN6D4cVWfVkPJ81xi50KqWFM-kNPgGHUHA93RQHcw0J0MXJXsH-WfA_-veQK8OZ8I
CitedBy_id crossref_primary_10_32604_or_2023_042383
crossref_primary_10_1038_s41467_024_53295_1
crossref_primary_10_3389_fimmu_2024_1401528
crossref_primary_10_3892_ol_2023_13950
crossref_primary_10_1002_wrna_1822
crossref_primary_10_1002_cti2_70014
crossref_primary_10_3390_pharmaceutics15010282
crossref_primary_10_4103_egjp_egjp_19_24
crossref_primary_10_1002_advs_202204998
crossref_primary_10_12677_acm_2025_154951
crossref_primary_10_3390_molecules28104224
crossref_primary_10_1007_s12032_023_02101_x
crossref_primary_10_3390_biomedicines12092152
crossref_primary_10_3389_fimmu_2024_1379622
crossref_primary_10_1007_s00277_024_05852_3
crossref_primary_10_3390_ijms25126595
crossref_primary_10_1158_1535_7163_MCT_24_0917
crossref_primary_10_1186_s12964_024_01562_5
crossref_primary_10_3390_molecules28052336
crossref_primary_10_1007_s13346_025_01893_x
crossref_primary_10_1007_s00277_025_06401_2
crossref_primary_10_1186_s12943_023_01735_9
crossref_primary_10_1002_adfm_202311677
crossref_primary_10_1007_s00432_024_05661_1
crossref_primary_10_3892_ol_2024_14389
crossref_primary_10_1080_15321819_2025_2464718
crossref_primary_10_3390_cancers14246150
crossref_primary_10_1093_postmj_qgaf072
crossref_primary_10_1136_jitc_2024_010326
Cites_doi 10.1182/blood-2011-11-391367
10.3389/fimmu.2013.00481
10.1002/cyto.b.20539
10.3389/fimmu.2019.00119
10.1111/trf.15033
10.1080/2162402X.2017.1312045
10.1083/jcb.200708043
10.1016/j.ymthe.2016.11.006
10.1182/blood-2008-01-134429
10.1074/jbc.M804860200
10.1172/jci.insight.134728
10.1021/jacs.0c05039
10.1038/nri1859
10.1038/sj.cdd.4402242
10.1371/journal.pone.0098358
10.1016/j.molcel.2008.05.026
10.1371/journal.pone.0137345
10.3389/fimmu.2017.00727
10.1136/jitc-2021-003737
10.4049/jimmunol.173.4.2562
10.1083/jcb.123.2.485
10.1016/j.cell.2009.05.046
10.1016/j.nano.2015.09.011
10.1016/j.critrevonc.2020.103014
10.1056/NEJMra0912273
10.1038/s41467-020-15129-8
10.1182/blood-2020-135941
10.1016/j.drudis.2020.11.003
10.1182/blood.V97.10.3146
10.1182/blood.V98.12.3346
10.1007/s00262-020-02812-4
10.4049/jimmunol.165.8.4624
10.3390/ijms18020441
10.1038/cdd.2008.185
10.1056/NEJMoa1807315
10.1016/j.tranon.2019.10.001
10.1016/j.ymthe.2021.01.006
10.3760/cma.i.issn.0529-5807.2012.10.019
10.1242/jcs.025015
10.1182/blood-2021-150606
10.4049/jimmunol.172.4.2578
10.3390/cancers13195019
10.3389/fimmu.2019.00811
10.1016/S0962-8924(00)01906-1
10.1083/jcb.132.3.437
10.1158/1538-7445.AM2021-1611
10.1074/jbc.M301869200
10.1080/2162402X.2022.2049486
10.1093/abt/tbaa017
10.1182/blood-2021-152896
10.1074/jbc.M104138200
10.1111/ejh.12439
10.4049/jimmunol.1102702
10.3233/JAD-2011-101014
10.1002/cam4.3768
10.1182/blood-2019-126271
10.3349/ymj.2016.57.6.1435
10.1128/JVI.00605-16
10.1038/s41568-019-0183-z
10.1186/s13148-017-0312-z
10.1021/acs.molpharmaceut.2c00073
10.1182/blood-2004-07-2823
10.4049/jimmunol.181.8.5204
10.1073/pnas.1121623109
10.1186/s13148-016-0220-7
10.4049/jimmunol.158.2.677
10.1182/blood-2001-12-0217
10.1182/blood.V87.1.180.bloodjournal871180
10.1182/blood-2020-134391
10.1038/s41590-017-0004-z
10.1097/CJI.0b013e318247440a
10.1136/jitc-2020-000905
10.1038/nn1997
10.1007/s40820-021-00647-x
10.1111/cas.14310
10.1016/j.it.2010.04.001
10.1073/pnas.1106550108
10.1038/s41598-019-46942-x
10.1158/1078-0432.CCR-19-1457
10.2174/138945008785909310
10.1038/nm.3931
10.18632/oncotarget.9899
10.1038/nature18935
10.1038/s41591-019-0356-z
10.1002/1521-4141(2000)30:8<2130::AID-IMMU2130>3.0.CO;2-8
10.1093/abt/tbaa006
10.1182/blood-2011-02-338020
10.1159/000464388
10.1186/s12951-020-0571-2
10.1182/blood-2011-10-386805
10.4049/jimmunol.167.5.2547
10.4049/jimmunol.180.12.8073
10.1126/science.288.5473.2051
10.1073/pnas.1209265109
10.1038/nature22076
10.1182/blood-2011-08-372425
10.1007/s13402-019-00469-5
10.1126/science.aar4060
10.1016/j.ejca.2017.02.013
10.1007/s12079-021-00646-y
10.1038/s41586-019-1456-0
10.1038/s41590-020-0728-z
10.3389/fimmu.2019.00252
10.1158/1078-0432.CCR-16-1700
10.1016/j.immuni.2007.11.011
10.1038/s41467-021-25475-w
10.1146/annurev-immunol-032713-120142
10.1523/jneurosci.23-07-02665.2003
10.1016/j.bbrep.2017.01.013
10.4049/jimmunol.164.4.2193
10.1126/scitranslmed.3001375
10.4049/jimmunol.175.12.7781
10.1016/j.blre.2018.04.005
10.3389/fimmu.2018.02985
10.1158/2326-6066.CIR-18-0367
10.1038/s41586-019-1593-5
10.1016/j.bbrc.2009.06.121
10.1038/nnano.2017.69
10.1073/pnas.92.9.3978
10.1182/blood-2019-122793
10.1182/blood-2008-03-143008
10.3389/fimmu.2019.01268
10.1007/s11302-006-9024-0
10.1016/j.cell.2010.07.044
10.1038/15233
10.1038/sj.emboj.7601415
10.1073/pnas.1710776114
10.1038/cdd.2014.86
10.1016/j.it.2017.12.005
10.1016/j.iotech.2022.1000705
10.1038/s41392-020-0121-2
10.1080/14712598.2022.2072209
10.1158/0008-5472.CAN-08-0186
10.1091/mbc.e13-01-0063
10.1016/j.celrep.2020.03.058
10.1126/science.2578228
10.4161/cc.10.1.14324
10.1126/science.aax0182
10.1371/journal.pone.0218897
10.1200/JCO.2020.38.15_suppl.3056
ContentType Journal Article
Copyright Copyright © 2022 Zhao, Song, Ma, Yan, Xie, Feng and Che.
Copyright © 2022 Zhao, Song, Ma, Yan, Xie, Feng and Che 2022 Zhao, Song, Ma, Yan, Xie, Feng and Che
Copyright_xml – notice: Copyright © 2022 Zhao, Song, Ma, Yan, Xie, Feng and Che.
– notice: Copyright © 2022 Zhao, Song, Ma, Yan, Xie, Feng and Che 2022 Zhao, Song, Ma, Yan, Xie, Feng and Che
DBID AAYXX
CITATION
7X8
5PM
DOA
DOI 10.3389/fimmu.2022.757480
DatabaseName CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic


CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1664-3224
ExternalDocumentID oai_doaj_org_article_37072b3a1bb5499ab0d2584e5645c3db
PMC9446754
10_3389_fimmu_2022_757480
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
AAYXX
ACGFO
ACGFS
ADBBV
ADRAZ
AENEX
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
EBS
EMOBN
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
OK1
PGMZT
RNS
RPM
7X8
5PM
ID FETCH-LOGICAL-c442t-f3c32731fcb97f67308ee55c6174d88a4ab530f8cc96c8a9fb3805e2508d45ba3
IEDL.DBID DOA
ISICitedReferencesCount 40
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000873989200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1664-3224
IngestDate Fri Oct 03 12:53:12 EDT 2025
Thu Aug 21 18:22:36 EDT 2025
Thu Sep 04 18:09:23 EDT 2025
Tue Nov 18 22:12:44 EST 2025
Sat Nov 29 03:27:59 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Language English
License This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c442t-f3c32731fcb97f67308ee55c6174d88a4ab530f8cc96c8a9fb3805e2508d45ba3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Edited by: Alessandro Poggi, San Martino Hospital (IRCCS), Italy
Reviewed by: Sukhbir Kaur, National Institutes of Health (NIH), United States; David Soto-Pantoja, Wake Forest School of Medicine, United States
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology
OpenAccessLink https://doaj.org/article/37072b3a1bb5499ab0d2584e5645c3db
PMID 36081498
PQID 2712846254
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_37072b3a1bb5499ab0d2584e5645c3db
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9446754
proquest_miscellaneous_2712846254
crossref_citationtrail_10_3389_fimmu_2022_757480
crossref_primary_10_3389_fimmu_2022_757480
PublicationCentury 2000
PublicationDate 2022-08-22
PublicationDateYYYYMMDD 2022-08-22
PublicationDate_xml – month: 08
  year: 2022
  text: 2022-08-22
  day: 22
PublicationDecade 2020
PublicationTitle Frontiers in immunology
PublicationYear 2022
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Barclay (B13) 2006; 6
Liu (B11) 2020
Feng (B22) 2020; 152
Qi (B129) 2020; 136
Liu (B54) 2015; 21
Logtenberg (B114) 2019; 25
Azcutia (B44) 2013; 24
Yuan (B105) 2017; 12
Liu (B101) 2015; 10
Mehta (B128) 2021; 138
Stefanidakis (B28) 2008; 112
Bamberger (B141) 2003; 23
Van (B48) 2012; 188
Zhao (B84) 2011; 108
Burger (B12) 2012; 119
Du (B139) 2021; 29
Foppoli (B133) 2015; 94
Low (B39) 1985; 227
Chen (B137) 2022
Barclay (B10) 2014; 32
Chow (B132) 2020; 38
Van (B56) 2008; 181
Miller (B109) 2019; 14
Poels (B4) 1986; 76
Cham (B53) 2020; 31
Lee (B69) 2016; 90
Tulasne (B19) 2001; 98
Russ (B46) 2018; 32
Topalian (B74) 2020; 367
Sallman (B125) 2019; 134
Jalil (B79) 2020; 3
Willingham (B87) 2012; 109
Murakami (B36) 2014; 21
Jaiswal (B94) 2010; 31
Zhao (B60) 2017; 8
Cooper (B72) 1995; 92
Wang (B135) 2022; 19
Bratosin (B41) 2011
Brown (B6) 2001; 11
Engelbertsen (B23) 2019; 9
Olsson (B32) 2008; 112
Németh (B96) 2019; 10
Crayne (B59) 2019; 10
Ingram (B119) 2017; 114
Wilson (B126) 2021; 138
Tsai (B16) 2008; 180
Fenalti (B3) 2021; 12
Chao (B104) 2010; 2
Ben Mkaddem (B95) 2019; 10
Shi (B123) 2020; 5
Wang (B1) 2021; 10
Huang (B58) 2017; 41
Leclair (B20) 2020; 111
Lamy (B82) 2003; 278
Jeanne (B90) 2021; 13
Zhong (B138) 2020; 13
Chao (B93) 2011; 118
Ribas (B75) 2018; 359
Kim (B131) 2020; 136
Autio (B134) 2020; 26
Ticchioni (B47) 1997; 158
Latour (B52) 2001; 167
Petrova (B116) 2017; 23
Bald (B68) 2020; 21
Lindberg (B2) 1993; 123
Bell (B63) 2016; 12
Vernon-Wilson (B15) 2000; 30
Kaur (B29) 2021
Brooke (B25) 2004; 173
Burton (B83) 2009; 16
Bresser (B115) 2022; 11
Huang (B122) 2021; 13
Veillette (B107) 2018; 39
Piccio (B27) 2005; 105
Oldenborg (B33) 2000; 288
Dheilly (B124) 2017; 25
Liu (B70) 2004; 172
Gao (B89) 2017; 8
Feng (B86) 2020; 152
Maute (B130) 2022; 13
Ma (B103) 2020; 18
Sarfati (B9) 2008; 9
Cooper (B98) 2001; 97
Nilsson (B43) 2009; 387
Kaur (B100) 2020; 3
Kaur (B31) 2011; 10
Demeure (B51) 2000; 164
Ni (B121) 2020; 142
Hatherley (B24) 2008; 31
Park (B35) 2008; 15
Stirnemann (B40) 2017; 18
Zhao (B113) 2017; 9
Meng (B127) 2019; 134
Zhao (B92) 2012; 109
Leclair (B21) 2014; 9
Nath (B64) 2018; 9
Przewoznik (B67) 2012; 35
von Roemeling (B106) 2020; 11
Oronsky (B112) 2016; 8
Ferlin (B136) 2021; 70
Weiskopf (B61) 2017; 76
Nath (B65) 2019; 7
Kim (B108) 2010; 363
Kobayashi (B34) 2007; 27
Mateo (B81) 2002; 100
Demaria (B77) 2019; 574
Bouguermouh (B50) 2008; 180
Jaiswal (B8) 2009; 138
Rodríguez-Jiménez (B55) 2019; 10
Isenberg (B17) 2009; 284
Chen (B102) 2017; 544
Simhadri (B37) 2012; 119
Pierson (B66) 1996; 87
van Beek (B14) 2005; 175
Hanisch (B26) 2007; 10
Feng (B45) 2019; 19
Van (B73) 2006; 25
Kojima (B140) 2016; 536
Mentlik James (B97) 2013; 4
Fisher (B117) 2008; 68
Hayat (B18) 2020; 43
Wang (B110) 2020; 8
Floden (B142) 2011; 25
Yu (B111) 2020
Chen (B118) 2022; 10
Kusakari (B42) 2008; 121
Parkos (B71) 1996; 132
McMichael (B99) 2017; 6
Zhang (B120) 2021; 81
Lee (B57) 2016; 57
Mateo (B80) 1999; 5
Avice (B49) 2000; 165
Liu (B7) 2001; 276
Chao (B88) 2010; 142
Zhao (B91) 2012; 119
Nguyen (B30) 2017; 9
Barkal (B85) 2018; 19
Velliquette (B38) 2019; 59
Cheng (B5) 2012; 41
Barkal (B78) 2019; 572
Ferrari (B62) 2007; 3
Advani (B76) 2018; 379
References_xml – volume: 119
  year: 2012
  ident: B91
  article-title: Is targeting of CD47-SIRPα enough for treating hematopoietic malignancy
  publication-title: Blood
  doi: 10.1182/blood-2011-11-391367
– volume: 4
  year: 2013
  ident: B97
  article-title: Combination immune therapies to enhance anti-tumor responses by NK cells
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2013.00481
– start-page: 28
  year: 2011
  ident: B41
  article-title: A cytometric study of the red blood cells in gaucher disease reveals their abnormal shape that may be involved in increased erythrophagocytosis
  publication-title: Cytom Part B Clin Cytom
  doi: 10.1002/cyto.b.20539
– volume: 10
  year: 2019
  ident: B59
  article-title: The immunology of macrophage activation syndrome
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2019.00119
– volume: 59
  year: 2019
  ident: B38
  article-title: Monoclonal anti-CD47 interference in red cell and platelet testing
  publication-title: Transfusion
  doi: 10.1111/trf.15033
– volume: 6
  year: 2017
  ident: B99
  article-title: Activation of the FcgammaReceptorIIIa on human natural killer cells leads to increased expression of functional interleukin-21 receptor
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2017.1312045
– volume: 180
  start-page: 989
  year: 2008
  ident: B16
  article-title: Inhibition of “self” engulfment through deactivation of myosin-II at the phagocytic synapse between human cells
  publication-title: J Cell Biol
  doi: 10.1083/jcb.200708043
– volume: 25
  year: 2017
  ident: B124
  article-title: Selective blockade of the ubiquitous checkpoint receptor CD47 is enabled by dual-targeting bispecific antibodies
  publication-title: Mol Ther
  doi: 10.1016/j.ymthe.2016.11.006
– volume: 112
  year: 2008
  ident: B28
  article-title: Endothelial CD47 interaction with SIRPγ is required for human T-cell transendothelial migration under shear flow conditions in vitro
  publication-title: Blood
  doi: 10.1182/blood-2008-01-134429
– volume: 284
  year: 2009
  ident: B17
  article-title: Differential interactions of thrombospondin-1, -2, and -4 with CD47 and effects on cGMP signaling and ischemic injury responses
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M804860200
– year: 2020
  ident: B11
  article-title: Targeting macrophage checkpoint inhibitor SIRPα for anticancer therapy
  publication-title: JCI Insight
  doi: 10.1172/jci.insight.134728
– volume: 142
  year: 2020
  ident: B121
  article-title: Nanoscale metal–organic framework Co-delivers TLR-7 agonists and anti-CD47 antibodies to modulate macrophages and orchestrate cancer immunotherapy
  publication-title: J Am Chem Soc
  doi: 10.1021/jacs.0c05039
– volume: 6
  year: 2006
  ident: B13
  article-title: The SIRP family of receptors and immune regulation
  publication-title: Nat Rev Immunol
  doi: 10.1038/nri1859
– volume: 15
  start-page: 192
  year: 2008
  ident: B35
  article-title: Rapid cell corpse clearance by stabilin-2, a membrane phosphatidylserine receptor
  publication-title: Cell Death Differ
  doi: 10.1038/sj.cdd.4402242
– volume: 9
  start-page: e98358
  year: 2014
  ident: B21
  article-title: CD47-independent effects mediated by the TSP-derived 4N1K peptide
  publication-title: PloS One
  doi: 10.1371/journal.pone.0098358
– volume: 31
  year: 2008
  ident: B24
  article-title: Paired receptor specificity explained by structures of signal regulatory proteins alone and complexed with CD47
  publication-title: Mol Cell
  doi: 10.1016/j.molcel.2008.05.026
– volume: 10
  year: 2015
  ident: B101
  article-title: Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential
  publication-title: PloS One
  doi: 10.1371/journal.pone.0137345
– volume: 8
  year: 2017
  ident: B60
  article-title: What else can CD39 tell us
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2017.00727
– volume: 10
  start-page: 1
  year: 2022
  ident: B118
  article-title: Delivery of CD47 blocker SIRPα-fc by CAR-T cells enhances antitumor efficacy
  publication-title: J Immunother Cancer
  doi: 10.1136/jitc-2021-003737
– volume: 173
  year: 2004
  ident: B25
  article-title: Human lymphocytes interact directly with CD47 through a novel member of the signal regulatory protein (SIRP) family
  publication-title: J Immunol
  doi: 10.4049/jimmunol.173.4.2562
– volume: 123
  year: 1993
  ident: B2
  article-title: Molecular cloning of integrin-associated protein: An immunoglobulin family member with multiple membrane-spanning domains implicated in α(v)β3- dependent ligand binding
  publication-title: J Cell Biol
  doi: 10.1083/jcb.123.2.485
– volume: 138
  year: 2009
  ident: B8
  article-title: CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis
  publication-title: Cell
  doi: 10.1016/j.cell.2009.05.046
– volume: 12
  year: 2016
  ident: B63
  article-title: Designer exosomes as next-generation cancer immunotherapy
  publication-title: Nanomed Nanotechnol Biol Med
  doi: 10.1016/j.nano.2015.09.011
– volume: 152
  year: 2020
  ident: B22
  article-title: CD47: The next checkpoint target for cancer immunotherapy
  publication-title: Crit Rev Oncol Hematol
  doi: 10.1016/j.critrevonc.2020.103014
– volume: 363
  year: 2010
  ident: B108
  article-title: Nanomedicine
  publication-title: N Engl J Med
  doi: 10.1056/NEJMra0912273
– volume: 11
  start-page: 1
  year: 2020
  ident: B106
  article-title: Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity
  publication-title: Nat Commun
  doi: 10.1038/s41467-020-15129-8
– volume: 136
  year: 2020
  ident: B131
  article-title: ALX148, a CD47 blocker, in combination with rituximab in patients with non-Hodgkin lymphoma
  publication-title: Blood
  doi: 10.1182/blood-2020-135941
– year: 2020
  ident: B111
  article-title: The development of small-molecule inhibitors targeting CD47
  publication-title: Drug Discov Today
  doi: 10.1016/j.drudis.2020.11.003
– volume: 97
  year: 2001
  ident: B98
  article-title: Human natural killer cells: A unique innate immunoregulatory role for the CD56bright subset
  publication-title: Blood
  doi: 10.1182/blood.V97.10.3146
– volume: 98
  year: 2001
  ident: B19
  article-title: C-terminal peptide of thrombospondin-1 induces platelet aggregation through the fc receptor γ-chain-associated signaling pathway and by agglutination
  publication-title: Blood
  doi: 10.1182/blood.V98.12.3346
– volume: 70
  year: 2021
  ident: B136
  article-title: Selective CD47 targeting with a bispecific antibody
  publication-title: Cancer Immunol Immunother
  doi: 10.1007/s00262-020-02812-4
– volume: 165
  year: 2000
  ident: B49
  article-title: CD47 ligation selectively inhibits the development of human naive T cells into Th1 effectors
  publication-title: J Immunol
  doi: 10.4049/jimmunol.165.8.4624
– volume: 18
  year: 2017
  ident: B40
  article-title: A review of gaucher disease pathophysiology, clinical presentation and treatments
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms18020441
– volume: 16
  year: 2009
  ident: B83
  article-title: The role of bcl-2 family member BNIP3 in cell death and disease: NIPping at the heels of cell death
  publication-title: Cell Death Differ
  doi: 10.1038/cdd.2008.185
– volume: 379
  year: 2018
  ident: B76
  article-title: CD47 blockade by Hu5F9-G4 and rituximab in non-hodgkin’s lymphoma
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1807315
– volume: 13
  start-page: 57
  year: 2020
  ident: B138
  article-title: Targeting tumor microenvironment by small-molecule inhibitors
  publication-title: Transl Oncol
  doi: 10.1016/j.tranon.2019.10.001
– volume: 29
  year: 2021
  ident: B139
  article-title: A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC
  publication-title: Mol Ther
  doi: 10.1016/j.ymthe.2021.01.006
– volume: 41
  year: 2012
  ident: B5
  article-title: Molecular pathology of lung cancer: Key to personalized medicine
  publication-title: Chin J Pathol
  doi: 10.3760/cma.i.issn.0529-5807.2012.10.019
– volume: 121
  year: 2008
  ident: B42
  article-title: Trans-endocytosis of CD47 and SHPS-1 and its role in regulation of the CD47-SHPS-1 system
  publication-title: J Cell Sci
  doi: 10.1242/jcs.025015
– volume: 138
  year: 2021
  ident: B128
  article-title: Lemzoparlimab, a differentiated anti-CD47 antibody in combination with rituximab in relapsed and refractory non-hodgkin’s lymphoma: Initial clinical results
  publication-title: Blood
  doi: 10.1182/blood-2021-150606
– volume: 172
  year: 2004
  ident: B70
  article-title: Peptide-mediated inhibition of neutrophil transmigration by blocking CD47 interactions with signal regulatory protein α
  publication-title: J Immunol
  doi: 10.4049/jimmunol.172.4.2578
– volume: 13
  year: 2021
  ident: B90
  article-title: Targeting ovarian carcinoma with TSP-1:CD47 antagonist TAX2 activates anti-tumor immunity
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers13195019
– volume: 10
  year: 2019
  ident: B95
  article-title: Understanding fc receptor involvement in inflammatory diseases: From mechanisms to new therapeutic tools
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2019.00811
– volume: 11
  year: 2001
  ident: B6
  article-title: Integrin-associated protein (CD47) and its ligands
  publication-title: Trends Cell Biol
  doi: 10.1016/S0962-8924(00)01906-1
– volume: 132
  year: 1996
  ident: B71
  article-title: CD47 mediates post-adhesive events required for neutrophil migration across polarized intestinal epithelia
  publication-title: J Cell Biol
  doi: 10.1083/jcb.132.3.437
– volume: 81
  year: 2021
  ident: B120
  article-title: Abstract 1611: A novel anti-human CD47 antibody prodrug as cancer therapeutics to lower on-target side effects
  publication-title: Cancer Res
  doi: 10.1158/1538-7445.AM2021-1611
– volume: 278
  year: 2003
  ident: B82
  article-title: CD47 and the 19 kDa interacting protein-3 (BNIP3) in T cell apoptosis
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M301869200
– volume: 11
  year: 2022
  ident: B115
  article-title: . QPCTL regulates macrophage and monocyte abundance and inflammatory signatures in the tumor microenvironment
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2022.2049486
– volume: 3
  year: 2020
  ident: B100
  article-title: Preclinical and clinical development of therapeutic antibodies targeting functions of CD47 in the tumor microenvironment
  publication-title: Antib Ther
  doi: 10.1093/abt/tbaa017
– volume: 138
  year: 2021
  ident: B126
  article-title: AO-176, a differentiated clinical-stage anti-CD47 antibody, demonstrates potent anti-tumor activity across multiple preclinical models of b cell neoplasms
  publication-title: Blood
  doi: 10.1182/blood-2021-152896
– volume: 276
  year: 2001
  ident: B7
  article-title: The role of CD47 in neutrophil transmigration
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M104138200
– volume: 94
  year: 2015
  ident: B133
  article-title: Gamma-delta t-cell lymphomas
  publication-title: Eur J Haematol
  doi: 10.1111/ejh.12439
– volume: 152
  start-page: 103014
  year: 2020
  ident: B86
  article-title: CD47: the next checkpoint target for cancer immunotherapy
  publication-title: Crit Rev Oncol Hematol
  doi: 10.1016/j.critrevonc.2020.103014
– volume: 188
  year: 2012
  ident: B48
  article-title: CD47 high expression on CD4 effectors identifies functional long-lived memory T cell progenitors
  publication-title: J Immunol
  doi: 10.4049/jimmunol.1102702
– volume: 25
  year: 2011
  ident: B142
  article-title: Microglia demonstrate age-dependent interaction with amyloid-β fibrils
  publication-title: J Alzheimer’s Dis
  doi: 10.3233/JAD-2011-101014
– volume: 10
  year: 2021
  ident: B1
  article-title: An antitumor peptide RS17-targeted CD47, design, synthesis, and antitumor activity
  publication-title: Cancer Med
  doi: 10.1002/cam4.3768
– volume: 134
  year: 2019
  ident: B125
  article-title: The first-in-Class anti-CD47 antibody magrolimab (5F9) in combination with azacitidine is effective in MDS and AML patients: Ongoing phase 1b results
  publication-title: Blood
  doi: 10.1182/blood-2019-126271
– volume: 57
  year: 2016
  ident: B57
  article-title: Upregulation of CD47 in regulatory T cells in atopic dermatitis
  publication-title: Yonsei Med J
  doi: 10.3349/ymj.2016.57.6.1435
– volume: 90
  year: 2016
  ident: B69
  article-title: CD47 plays a role as a negative regulator in inducing protective immune responses to vaccination against influenza virus
  publication-title: J Virol
  doi: 10.1128/JVI.00605-16
– volume: 19
  year: 2019
  ident: B45
  article-title: Phagocytosis checkpoints as new targets for cancer immunotherapy
  publication-title: Nat Rev Cancer
  doi: 10.1038/s41568-019-0183-z
– volume: 9
  start-page: 4
  year: 2017
  ident: B113
  article-title: The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry
  publication-title: Clin Epigenet
  doi: 10.1186/s13148-017-0312-z
– volume: 19
  year: 2022
  ident: B135
  article-title: Recent advances of tumor therapy based on the CD47-SIRPα axis
  publication-title: Mol Pharm
  doi: 10.1021/acs.molpharmaceut.2c00073
– volume: 105
  year: 2005
  ident: B27
  article-title: Adhesion of human T cells to antigen-presenting cells through SIRPβ2-CD47 interaction costimulates T-cell proliferation
  publication-title: Blood
  doi: 10.1182/blood-2004-07-2823
– volume: 181
  year: 2008
  ident: B56
  article-title: Cutting edge: CD47 controls the In vivo proliferation and homeostasis of peripheral CD4 + CD25 + Foxp3 + regulatory T cells that express CD103
  publication-title: J Immunol
  doi: 10.4049/jimmunol.181.8.5204
– volume: 109
  year: 2012
  ident: B87
  article-title: The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
  publication-title: Proc Natl Acad Sci
  doi: 10.1073/pnas.1121623109
– volume: 8
  start-page: 53
  year: 2016
  ident: B112
  article-title: RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors
  publication-title: Clin Epigenet
  doi: 10.1186/s13148-016-0220-7
– volume: 158
  year: 1997
  ident: B47
  article-title: Integrin-associated protein (CD47) is a comitogenic molecule on CD3-activated human T cells
  publication-title: J Immunol
  doi: 10.4049/jimmunol.158.2.677
– volume: 100
  year: 2002
  ident: B81
  article-title: Mechanisms of CD47-induced caspase-independent cell death in normal and leukemic cells: Link between phosphatidylserine exposure and cytoskeleton organization
  publication-title: Blood
  doi: 10.1182/blood-2001-12-0217
– volume: 76
  year: 1986
  ident: B4
  article-title: Monoclonal antibody against human ovarian tumor-associated antigens
  publication-title: J Natl Cancer Inst
– volume: 87
  year: 1996
  ident: B66
  article-title: Human natural killer cell expansion is regulated by thrombospondin- mediated activation of transforming growth factor-beta 1 and independent accessory cell-derived contact and soluble factors
  publication-title: Blood
  doi: 10.1182/blood.V87.1.180.bloodjournal871180
– volume: 136
  year: 2020
  ident: B129
  article-title: A phase I/IIa study of lemzoparlimab, a monoclonal antibody targeting CD47, in patients with relapsed and/or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): Initial phase I results
  publication-title: Blood
  doi: 10.1182/blood-2020-134391
– volume: 19
  start-page: 76
  year: 2018
  ident: B85
  article-title: Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy
  publication-title: Nat Immunol
  doi: 10.1038/s41590-017-0004-z
– volume: 35
  year: 2012
  ident: B67
  article-title: Recruitment of natural killer cells in advanced stages of endogenously arising b-cell lymphoma
  publication-title: J Immunother
  doi: 10.1097/CJI.0b013e318247440a
– volume: 8
  start-page: 1
  year: 2020
  ident: B110
  article-title: CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy
  publication-title: J Immunother Cancer
  doi: 10.1136/jitc-2020-000905
– volume: 10
  year: 2007
  ident: B26
  article-title: Microglia: Active sensor and versatile effector cells in the normal and pathologic brain
  publication-title: Nat Neurosci
  doi: 10.1038/nn1997
– volume: 13
  start-page: 141
  year: 2021
  ident: B122
  article-title: Time-programmed delivery of sorafenib and anti-CD47 antibody via a double-Layer-Gel matrix for postsurgical treatment of breast cancer
  publication-title: Nano-Micro Lett
  doi: 10.1007/s40820-021-00647-x
– volume: 111
  year: 2020
  ident: B20
  article-title: Peptide analogues PKHB1 and 4N1K induce cell death through CD47-independent mechanisms
  publication-title: Cancer Sci
  doi: 10.1111/cas.14310
– volume: 31
  year: 2010
  ident: B94
  article-title: Macrophages as mediators of tumor immunosurveillance
  publication-title: Trends Immunol
  doi: 10.1016/j.it.2010.04.001
– volume: 108
  year: 2011
  ident: B84
  article-title: CD47-signal regulatory protein- (SIRP) interactions form a barrier for antibody-mediated tumor cell destruction
  publication-title: Proc Natl Acad Sci
  doi: 10.1073/pnas.1106550108
– volume: 9
  start-page: 10608
  year: 2019
  ident: B23
  article-title: Increased lymphocyte activation and atherosclerosis in CD47-deficient mice
  publication-title: Sci Rep
  doi: 10.1038/s41598-019-46942-x
– volume: 26
  year: 2020
  ident: B134
  article-title: Probody therapeutics: An emerging class of therapies designed to enhance on-target effects with reduced off-tumor toxicity for use in immuno-oncology
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-19-1457
– volume: 9
  year: 2008
  ident: B9
  article-title: CD47 in the immune response: Role of thrombospondin and SIRP-α reverse signaling
  publication-title: Curr Drug Targets
  doi: 10.2174/138945008785909310
– volume: 21
  year: 2015
  ident: B54
  article-title: CD47 blockade triggers T cell–mediated destruction of immunogenic tumors
  publication-title: Nat Med
  doi: 10.1038/nm.3931
– volume: 8
  year: 2017
  ident: B89
  article-title: CD47 deficiency in tumor stroma promotes tumor progression by enhancing angiogenesis
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.9899
– volume: 536
  start-page: 86
  year: 2016
  ident: B140
  article-title: CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis
  publication-title: Nature
  doi: 10.1038/nature18935
– volume: 25
  year: 2019
  ident: B114
  article-title: Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapy
  publication-title: Nat Med
  doi: 10.1038/s41591-019-0356-z
– volume: 30
  year: 2000
  ident: B15
  article-title: CD47 is a ligand for rat macrophage membrane signal regulatory protein SIRP (OX41) and human SIRPalpha 1
  publication-title: Eur J Immunol
  doi: 10.1002/1521-4141(2000)30:8<2130::AID-IMMU2130>3.0.CO;2-8
– volume: 3
  year: 2020
  ident: B79
  article-title: Macrophage checkpoint blockade: results from initial clinical trials, binding analyses, and CD47-SIRPα structure–function
  publication-title: Antib Ther
  doi: 10.1093/abt/tbaa006
– volume: 118
  year: 2011
  ident: B93
  article-title: Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy
  publication-title: Blood
  doi: 10.1182/blood-2011-02-338020
– volume: 41
  year: 2017
  ident: B58
  article-title: Treg cells protect dopaminergic neurons against MPP + neurotoxicity via CD47-SIRPA interaction
  publication-title: Cell Physiol Biochem
  doi: 10.1159/000464388
– volume: 18
  year: 2020
  ident: B103
  article-title: Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential
  publication-title: J Nanobiotechnol
  doi: 10.1186/s12951-020-0571-2
– volume: 119
  year: 2012
  ident: B12
  article-title: CD47 functions as a molecular switch for erythrocyte phagocytosis
  publication-title: Blood
  doi: 10.1182/blood-2011-10-386805
– volume: 167
  year: 2001
  ident: B52
  article-title: Bidirectional negative regulation of human T and dendritic cells by CD47 and its cognate receptor signal-regulator protein-α: Down-regulation of IL-12 responsiveness and inhibition of dendritic cell activation
  publication-title: J Immunol
  doi: 10.4049/jimmunol.167.5.2547
– volume: 180
  year: 2008
  ident: B50
  article-title: CD47 expression on T cell is a self-control negative regulator of type 1 immune response
  publication-title: J Immunol
  doi: 10.4049/jimmunol.180.12.8073
– volume: 288
  year: 2000
  ident: B33
  article-title: Role of CD47 as a marker of self on red blood cells
  publication-title: Science (80-)
  doi: 10.1126/science.288.5473.2051
– volume: 109
  year: 2012
  ident: B92
  article-title: On the mechanism of CD47 targeting in cancer
  publication-title: Proc Natl Acad Sci
  doi: 10.1073/pnas.1209265109
– volume: 544
  year: 2017
  ident: B102
  article-title: SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via mac-1 integrin
  publication-title: Nature
  doi: 10.1038/nature22076
– volume: 119
  year: 2012
  ident: B37
  article-title: Human CD300a binds to phosphatidylethanolamine and phosphatidylserine, and modulates the phagocytosis of dead cells
  publication-title: Blood
  doi: 10.1182/blood-2011-08-372425
– volume: 43
  start-page: 19
  year: 2020
  ident: B18
  article-title: CD47: Role in the immune system and application to cancer therapy
  publication-title: Cell Oncol
  doi: 10.1007/s13402-019-00469-5
– volume: 359
  year: 2018
  ident: B75
  article-title: Cancer immunotherapy using checkpoint blockade
  publication-title: Science (80-)
  doi: 10.1126/science.aar4060
– volume: 76
  year: 2017
  ident: B61
  article-title: Cancer immunotherapy targeting the CD47/SIRPα axis
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2017.02.013
– year: 2021
  ident: B29
  article-title: CD47 interactions with exportin-1 limit the targeting of m7G-modified RNAs to extracellular vesicles
  publication-title: J Cell Commun Signal
  doi: 10.1007/s12079-021-00646-y
– volume: 572
  year: 2019
  ident: B78
  article-title: CD24 signalling through macrophage siglec-10 is a target for cancer immunotherapy
  publication-title: Nature
  doi: 10.1038/s41586-019-1456-0
– volume: 21
  year: 2020
  ident: B68
  article-title: The NK cell–cancer cycle: advances and new challenges in NK cell–based immunotherapies
  publication-title: Nat Immunol
  doi: 10.1038/s41590-020-0728-z
– volume: 10
  year: 2019
  ident: B96
  article-title: Importance of fc receptor γ-chain ITAM tyrosines in neutrophil activation and in vivo autommune arthritis
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2019.00252
– volume: 23
  year: 2017
  ident: B116
  article-title: TTI-621 (SIRPαFc): A CD47-blocking innate immune checkpoint inhibitor with broad antitumor activity and minimal erythrocyte binding
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-16-1700
– volume: 27
  year: 2007
  ident: B34
  article-title: TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells
  publication-title: Immunity
  doi: 10.1016/j.immuni.2007.11.011
– volume: 12
  start-page: 5218
  year: 2021
  ident: B3
  article-title: Structure of the human marker of self 5-transmembrane receptor CD47
  publication-title: Nat Commun
  doi: 10.1038/s41467-021-25475-w
– volume: 32
  start-page: 25
  year: 2014
  ident: B10
  article-title: The interaction between signal regulatory protein alpha (SIRP α) and CD47: Structure, function, and therapeutic target
  publication-title: Annu Rev Immunol
  doi: 10.1146/annurev-immunol-032713-120142
– volume: 23
  year: 2003
  ident: B141
  article-title: A cell surface receptor complex for fibrillar β-amyloid mediates microglial activation
  publication-title: J Neurosci
  doi: 10.1523/jneurosci.23-07-02665.2003
– volume: 9
  year: 2017
  ident: B30
  article-title: Investigation of the adaptor protein PLIC-2 in multiple pathways
  publication-title: Biochem Biophys Rep
  doi: 10.1016/j.bbrep.2017.01.013
– volume: 164
  year: 2000
  ident: B51
  article-title: CD47 engagement inhibits cytokine production and maturation of human dendritic cells
  publication-title: J Immunol
  doi: 10.4049/jimmunol.164.4.2193
– volume: 2
  year: 2010
  ident: B104
  article-title: Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47
  publication-title: Sci Transl Med
  doi: 10.1126/scitranslmed.3001375
– volume: 175
  year: 2005
  ident: B14
  article-title: Signal regulatory proteins in the immune system
  publication-title: J Immunol
  doi: 10.4049/jimmunol.175.12.7781
– volume: 32
  year: 2018
  ident: B46
  article-title: Blocking “don’t eat me” signal of CD47-SIRPα in hematological malignancies, an in-depth review
  publication-title: Blood Rev
  doi: 10.1016/j.blre.2018.04.005
– volume: 9
  year: 2018
  ident: B64
  article-title: CD47 expression in natural killer cells regulates homeostasis and modulates immune response to lymphocytic choriomeningitis virus
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2018.02985
– volume: 7
  year: 2019
  ident: B65
  article-title: Natural killer cell recruitment and activation are regulated by cd47 expression in the tumor microenvironment
  publication-title: Cancer Immunol Res
  doi: 10.1158/2326-6066.CIR-18-0367
– volume: 574
  start-page: 45
  year: 2019
  ident: B77
  article-title: Harnessing innate immunity in cancer therapy
  publication-title: Nature
  doi: 10.1038/s41586-019-1593-5
– volume: 387
  start-page: 58
  year: 2009
  ident: B43
  article-title: CD47 promotes both phosphatidylserine-independent and phosphatidylserine-dependent phagocytosis of apoptotic murine thymocytes by non-activated macrophages
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2009.06.121
– volume: 12
  year: 2017
  ident: B105
  article-title: Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy
  publication-title: Nat Nanotechnol
  doi: 10.1038/nnano.2017.69
– volume: 92
  year: 1995
  ident: B72
  article-title: Transendothelial migration of neutrophils involves integrin-associated protein (CD47)
  publication-title: Proc Natl Acad Sci
  doi: 10.1073/pnas.92.9.3978
– volume: 134
  year: 2019
  ident: B127
  article-title: TJC4, a differentiated anti-CD47 antibody with novel epitope and RBC sparing properties
  publication-title: Blood
  doi: 10.1182/blood-2019-122793
– volume: 112
  year: 2008
  ident: B32
  article-title: CD47 on experimentally senescent murine RBCs inhibits phagocytosis following fcγ receptor-mediated but not scavenger receptor-mediated recognition by macrophages
  publication-title: Blood
  doi: 10.1182/blood-2008-03-143008
– volume: 10
  year: 2019
  ident: B55
  article-title: Thrombospondin-1/CD47 interaction regulates Th17 and treg differentiation in psoriasis
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2019.01268
– volume: 3
  start-page: 99
  year: 2007
  ident: B62
  article-title: Shaping immune responses through the activation of dendritic cells’ P2 receptors
  publication-title: Purinergic Signal
  doi: 10.1007/s11302-006-9024-0
– volume: 142
  start-page: 699
  year: 2010
  ident: B88
  article-title: Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma
  publication-title: Cell
  doi: 10.1016/j.cell.2010.07.044
– volume: 5
  year: 1999
  ident: B80
  article-title: CD47 ligation induces caspase-independent cell death in chronic lymphocytic leukemia
  publication-title: Nat Med
  doi: 10.1038/15233
– volume: 25
  year: 2006
  ident: B73
  article-title: Expression of the self-marker CD47 on dendritic cells governs their trafficking to secondary lymphoid organs
  publication-title: EMBO J
  doi: 10.1038/sj.emboj.7601415
– volume: 114
  start-page: 201710776
  year: 2017
  ident: B119
  article-title: Localized CD47 blockade enhances immunotherapy for murine melanoma
  publication-title: Proc Natl Acad Sci
  doi: 10.1073/pnas.1710776114
– volume: 21
  year: 2014
  ident: B36
  article-title: CD300b regulates the phagocytosis of apoptotic cells via phosphatidylserine recognition
  publication-title: Cell Death Differ
  doi: 10.1038/cdd.2014.86
– volume: 39
  year: 2018
  ident: B107
  article-title: SIRPα–CD47 immune checkpoint blockade in anticancer therapy
  publication-title: Trends Immunol
  doi: 10.1016/j.it.2017.12.005
– volume: 13
  start-page: 100070
  year: 2022
  ident: B130
  article-title: CD47–SIRPα-targeted therapeutics: Status and prospects
  publication-title: Immuno-Oncology Technol
  doi: 10.1016/j.iotech.2022.1000705
– volume: 5
  start-page: 16
  year: 2020
  ident: B123
  article-title: The identification of a CD47-blocking “hotspot” and design of a CD47/PD-L1 dual-specific antibody with limited hemagglutination
  publication-title: Signal Transduct Target Ther
  doi: 10.1038/s41392-020-0121-2
– start-page: 1
  year: 2022
  ident: B137
  article-title: Bispecific antibodies for immune cell retargeting against cancer
  publication-title: Expert Opin Biol Ther
  doi: 10.1080/14712598.2022.2072209
– volume: 68
  year: 2008
  ident: B117
  article-title: Biological research in the evolution of cancer surgery: A personal perspective
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-08-0186
– volume: 24
  year: 2013
  ident: B44
  article-title: CD47 plays a critical role in T-cell recruitment by regulation of LFA-1 and VLA-4 integrin adhesive functions
  publication-title: Mol Biol Cell
  doi: 10.1091/mbc.e13-01-0063
– volume: 31
  start-page: 107494
  year: 2020
  ident: B53
  article-title: Immunotherapeutic blockade of CD47 inhibitory signaling enhances innate and adaptive immune responses to viral infection
  publication-title: Cell Rep
  doi: 10.1016/j.celrep.2020.03.058
– volume: 227
  year: 1985
  ident: B39
  article-title: The role of hemoglobin denaturation and band 3 clustering in red blood cell aging
  publication-title: Science (80-)
  doi: 10.1126/science.2578228
– volume: 10
  year: 2011
  ident: B31
  article-title: CD47 applies the brakes to angiogenesis via vascular endothelial growth factor receptor-2
  publication-title: Cell Cycle
  doi: 10.4161/cc.10.1.14324
– volume: 367
  year: 2020
  ident: B74
  article-title: Neoadjuvant checkpoint blockade for cancer immunotherapy
  publication-title: Science (80-)
  doi: 10.1126/science.aax0182
– volume: 14
  year: 2019
  ident: B109
  article-title: Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors
  doi: 10.1371/journal.pone.0218897
– volume: 38
  year: 2020
  ident: B132
  article-title: A phase I study of ALX148, a CD47 blocker, in combination with standard anticancer antibodies and chemotherapy regimens in patients with advanced malignancy
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2020.38.15_suppl.3056
SSID ssj0000493335
Score 2.4923005
SecondaryResourceType review_article
Snippet CD47 is ubiquitously expressed on the surface of cells and plays a critical role in self-recognition. By interacting with SIRPα, TSP-1 and integrins, CD47...
SourceID doaj
pubmedcentral
proquest
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 757480
SubjectTerms atherosclerosis
cancer immunotherapy
CD47
immune modulation
Immunology
immunotherapies
SIRPα
Title CD47 as a promising therapeutic target in oncology
URI https://www.proquest.com/docview/2712846254
https://pubmed.ncbi.nlm.nih.gov/PMC9446754
https://doaj.org/article/37072b3a1bb5499ab0d2584e5645c3db
Volume 13
WOSCitedRecordID wos000873989200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 1664-3224
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000493335
  issn: 1664-3224
  databaseCode: DOA
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 1664-3224
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000493335
  issn: 1664-3224
  databaseCode: M~E
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV27TuwwEB0BAonmiqdYLiAjUSEFgh-xU_IUBSAKQNtZtmOLRZBF7O6VaO63M44XlDTQ0LhIHMc5k2TOxJMzAHtU-cjjRcZd5bARLFPW0awyrDCCWhmaBNmHK3lzo_r98rZV6ivmhCV54ATcIZO5pJaZI2tjKGNsXlF0mj6qoDhW2fj2RdbTCqaeEu9ljIm0jIlRWHkYBi8vE4wHKT2QQvIoA9lyRI1ef4dkdlMkWz7nYgn-TMkiOU6TXIYZX6_AQiof-b4K9PSMS2JGxBAcEQ2Gboi0fqgiKc2bDGoyrBt16vc1uL84vzu9zKY1EDLHOR1ngTmGDOMoOFvKUODzqLwXwiHx4JVShhsrWB6Uc2XhlCmDZSoXHomNqriwhq3DXD2s_QYQHMj4QrDKs8ADMsOiohI7IiZKOmN7kH8Cot1UIDzWqXjWGChEDHWDoY4Y6oRhD_a_DnlN6hjfdT6JKH91jMLWzQY0t56aW_9k7h7sftpII65xdcPUfjgZaSqjq8VwjvdAdozXOWN3Tz14bCS1S4yKpeCbvzHFv7AYrzp-eKZ0C-bGbxO_DfPu33gwetuBWdlXO83diu31__MPFnbu-A
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=CD47+as+a+promising+therapeutic+target+in+oncology&rft.jtitle=Frontiers+in+immunology&rft.au=Zhao%2C+Hai&rft.au=Song%2C+Shuangshuang&rft.au=Ma%2C+Junwei&rft.au=Yan%2C+Zhiyong&rft.date=2022-08-22&rft.issn=1664-3224&rft.eissn=1664-3224&rft.volume=13&rft_id=info:doi/10.3389%2Ffimmu.2022.757480&rft.externalDBID=n%2Fa&rft.externalDocID=10_3389_fimmu_2022_757480
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3224&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3224&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3224&client=summon